Do you want to read an article? Please log in or register.
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
J Thorac Oncol
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT
doi: 10.1016/j.jtho.2024.09.1443
EHA 2024
Leukemia
RESONATE-2: Sustained survival benefit with first-line ibrutinib in older patients with CLL with up to ten years of follow-up
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE
doi: 10.1016/j.lungcan.2024.107929
ELCC 2025
Lung, Respiratory and Thoracic Cancer
SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
Leukemia
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B
doi: 10.1016/S1470-2045(24)00196-7
Lung, Respiratory and Thoracic Cancer
Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?
Lung Cancer
Heijboer FWJ, Mulders TA, van Straten M, Moonen L, Speel EM, von der Thüsen JH, Derks JL, Dingemans AC
doi: 10.1016/j.lungcan.2024.108030
Lung, Respiratory and Thoracic Cancer
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
J Thorac Oncol
Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D
doi: 10.1016/j.jtho.2024.06.008
Radio-Oncology
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy
Neuro Oncol
Buchner JA, Kofler F, Mayinger M, Christ SM, Brunner TB, Wittig A, Menze B, Zimmer C, Meyer B, Guckenberger M, Andratschke N, El Shafie RA, Debus J, Rogers S, Riesterer O, Schulze K, Feldmann HJ, Blanck O, Zamboglou C, Ferentinos K, Bilger-Zähringer A, Grosu AL, Wolff R, Piraud M, Eitz KA, Combs SE, Bernhardt D, Rueckert D, Wiestler B, Peeken JC
doi: 10.1093/neuonc/noae098